Ginkgo Biloba
An effective treatment for stimulating memory and concentration
Standardised in flavone glycosides 24% and 6% terpene lactones
18,90 €
Expiration date (End Of): 02/2022 |
Lot: D13590 | Ref. GG24
1 unit
3 + 1 free
Buy Ginkgo Biloba
60 mg / 120 capsules
Add to basketThis product allows you to accumulate 18 loyalty points. 18 points = 1,08€.
Description: Ginkgo Biloba
Health claims
Standardised ginkgo leaf extract is recognised by the Commission E and by the World Health Organization as an adjuvant treatment for symptoms of vascular and degenerative dementia, including memory loss, attention deficits and depression.
Known for several thousand years Ginkgo biloba has many medical applications. It improves capillary and venous circulation, helps with memory problems, senility, skin disorders, varicose veins, haemorrhoids and heavy legs.
It also significantly improves cognitive function in the over 50s. Its effectiveness is due to the flavonol glycosides and the terpene lactones that it contains.
The flavonoid glycoside and terpene lactone (ginkgolides and bilobalides) content of our gingko biloba exceeds the minimum 24% and 6% required for therapeutic efficacy. This makes it an exceptionally high quality pharmaceutical product.
Ginkgo Biloba: Detailed information
Appearing before the dinosaurs and surviving all climate changes and even nuclear bombs, Gingko biloba (ginkgo from the Chinese words ‘yin’ meaning ‘silver’ and ‘kuo’ meaning ‘fruit’ and biloba describing the characteristic shape of its leaves with two lobes) has had many medical applications for almost 6 thousand years.
Its effectiveness is due to the flavonol glycosides and terpene lactones that it contains.
Flavonol glycosides inhibit blood coagulation factors and stimulate the circulation, which improves blood flow and capillary and venous circulation as well as varicose veins, hemorrhoids and heavy legs. They also inhibit free radicals.
Gingkgolides and bilobalides (terpene lactones) improve cerebral glucose metabolism and are therefore beneficial in case of memory problems, senility and skin disorders.
Taking gingko biloba in the early stages of Alzheimer’s slows down the progression of the disease. It also significantly improves cognitive function in the over 50s. Chinese medicine also makes a remedy for the lungs from gingko biloba leaf extract that is effective in case of asthma.
Several extracts on the market are only pale imitations of those used in trials (EGb 761 and Li 1370): they are generally standardised in terms of glucoflavonoid content, but not in terms of terpene lactones content. Moreover, capsules or tablets containing only dried leaves, tinctures and non-standardised extracts cannot provide the same doses as these extracts.
Ingredients: Ginkgo Biloba
Consulting batch information
Consulting batch information†N/A: Not applicable
Other ingredients:
Maltodextrin, vegetable-based capsule: hydroxypropyl methylcellulose.
Food allergens:
This product does not contain allergens (in accordance with Regulation (EU) No 1169/2011) nor genetically modified organisms.
Use: Ginkgo Biloba Consulting batch information
Consulting batch informationDIRECTIONS:
1 capsule per day with half a glass of water at mealtime.
WARNINGS:
Consult your doctor in case of simultaneous use of anticoagulants. Not recommended for people undergoing antidepressive treatment. Do not use in case of pregnant or lactating women. Do not exceed the recommended daily dose.
ADVICES:
Does not replace a varied and balanced diet and a healthy lifestyle. If you are undergoing medical treatment, seek your therapist's advice. For adult use only. Keep out of reach of young children.
STORAGE INSTRUCTIONS:
Store in a cool dry place away from sunlight.
Quality: Ginkgo Biloba Consulting batch information
Consulting batch informationPRODUCT NAME
Ginkgo BilobaBOTANICAL NAME
Ginkgo biloba L.REFERENCE
GG24QUANTITY
120 capsulesBATCH NUMBER
D13590EXPIRATION DATE
2022/02MADE
In FranceSERVINGS PER CONTAINER
120 servingsFABRICATION AND GUARANTEE:
This dietary supplement is manufactured by a GMP-compliant laboratory (GMPs are the Good Manufacturing Practice guidelines for the European pharmaceutical industry).
Their active principle content is guaranteed through regular tests, which can be viewed online.
The labelling of our products complies with Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 and its subsequent amendments, with the aim of ensuring a high level of consumer protection in relation to food information.
Our packaging complies with Regulation (EC) No 1935/2004 of the European Parliament and of the Council of 27 October 2004 and its subsequent amendments on materials and articles intended to come into contact with food, aiming to secure a high level of protection of human health and the interests of consumers.
CHARACTERISTICS:
VEGETABLE CAPSULES
NOT IRRADIATED
WITHOUT ADDITIVES
WITHOUT ALLERGENS
WITHOUT BPA
NO OMG
WITHOUT LACTOSE
VEGAN
PRODUCT ANALYSIS:
ORGANOLEPTIC QUALITY
SPECIFICATIONS
RESULTS
ANALYTICAL QUALITY
SPECIFICATIONS
RESULTS
MICROBIOLOGICAL QUALITY
SPECIFICATIONS
RESULTS
PRODUCT REGISTRATION:
Anastore is registered on the Food Safety Register of Food Business Operators, whose purpose is to protect public health and consumer interests, where the definitions provided for in Articles 2 and 3 of Regulation (EC) No 178/2002 and Article 2 of Regulation (EC) No 852/2004 of the European Parliament and of the Council, and their subsequent amendments, are applicable.
These Regulations lay down the general principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food safety, in addition to laying down general rules in relation to the hygiene of foodstuffs.
Finally, Anastore notifies the placing on the market of its food supplements in accordance with the specific regulations of each country.
Registration Information
The notification of placing on the market of this product has been made under notification number PL 2081/10.
HEAD OF THE QUALITY DEPARTMENT
Certificate issue date: 2020/04/02
